DK2132229T3 - Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS - Google Patents

Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS Download PDF

Info

Publication number
DK2132229T3
DK2132229T3 DK08706941.5T DK08706941T DK2132229T3 DK 2132229 T3 DK2132229 T3 DK 2132229T3 DK 08706941 T DK08706941 T DK 08706941T DK 2132229 T3 DK2132229 T3 DK 2132229T3
Authority
DK
Denmark
Prior art keywords
antibody
egfr
antibodies
cells
composition
Prior art date
Application number
DK08706941.5T
Other languages
Danish (da)
English (en)
Inventor
Mikkel Wandahl Pedersen
Klaus Koefoed
Lars Soegaard Nielsen
Per-Johan Meijer
Allan Jensen
Lucilla Steinaa
Robert Carlsson
Charles Pyke
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39495833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2132229(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symphogen As filed Critical Symphogen As
Application granted granted Critical
Publication of DK2132229T3 publication Critical patent/DK2132229T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK08706941.5T 2007-03-01 2008-02-27 Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS DK2132229T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200700317 2007-03-01
US90477307P 2007-03-05 2007-03-05
DKPA200701016 2007-07-10
US92972707P 2007-07-11 2007-07-11
PCT/DK2008/050047 WO2008104183A2 (en) 2007-03-01 2008-02-27 Recombinant anti-epidermal growth factor receptor antibody compositions

Publications (1)

Publication Number Publication Date
DK2132229T3 true DK2132229T3 (en) 2016-06-20

Family

ID=39495833

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08706941.5T DK2132229T3 (en) 2007-03-01 2008-02-27 Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS

Country Status (18)

Country Link
US (3) US7887805B2 (enExample)
EP (2) EP2132229B1 (enExample)
JP (1) JP5726417B2 (enExample)
KR (2) KR101676622B1 (enExample)
CN (2) CN101675075B (enExample)
AU (1) AU2008221118B2 (enExample)
BR (1) BRPI0808551B1 (enExample)
CA (1) CA2676049C (enExample)
DK (1) DK2132229T3 (enExample)
ES (1) ES2582386T3 (enExample)
HK (1) HK1197252A1 (enExample)
IL (2) IL199725A (enExample)
MX (2) MX338151B (enExample)
NZ (2) NZ597466A (enExample)
PL (1) PL2132229T3 (enExample)
RU (1) RU2013119724A (enExample)
TW (1) TWI426083B (enExample)
WO (1) WO2008104183A2 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2677771A1 (en) * 2007-03-01 2008-09-04 Symphogen A/S Method for cloning cognate antibodies
MX338151B (es) 2007-03-01 2016-04-05 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
US20090203038A1 (en) * 2007-12-27 2009-08-13 Abbott Laboratories Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays
CN102137874B (zh) * 2008-08-29 2015-02-18 西福根有限公司 抗表皮生长因子受体的重组抗体组合物
WO2010022738A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
MX2011003480A (es) * 2008-10-06 2011-04-21 Symphogen As Metodo para identificar y seleccionar candidatos de farmaco para productos de farmacos de combinacion.
FR2942928B1 (fr) 2009-03-03 2011-04-01 Alcatel Lucent Procede et systeme de gestion multicriteres de notifications de presence
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
EP2486411A2 (en) * 2009-10-09 2012-08-15 Symphogen A/S Multiplex quantitation of individual recombinant proteins in a mixture by signature peptides and mass spectrometry
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
EP3085387A1 (en) 2010-04-26 2016-10-26 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
WO2011140151A1 (en) * 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
EP2566512A1 (en) * 2010-05-04 2013-03-13 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
US8790649B2 (en) 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
EP3156421B1 (en) 2010-11-01 2018-06-06 Symphogen A/S Pan-her antibody composition
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
DK2683736T3 (en) 2011-03-09 2018-04-23 Cell Signaling Technology Inc METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES
AU2012229147B2 (en) 2011-03-11 2015-12-24 Merrimack Pharmaceuticals, Inc. Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
US20150231238A1 (en) 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
US20120258502A1 (en) * 2011-04-08 2012-10-11 Vinod Pandiripally Method of producing recombinant plasmid dna using substantially solid growth medium
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
WO2013106489A1 (en) * 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
MX358728B (es) 2012-05-02 2018-09-03 Symphogen As Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
CN104903726A (zh) * 2012-09-05 2015-09-09 Jsr株式会社 对细胞的上皮性维持起作用的物质的筛选方法
US20150293105A1 (en) * 2012-10-26 2015-10-15 The University Of Queensland Methods for classifying tumors and uses therefor
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
CN104059148B (zh) * 2013-03-18 2016-09-07 回而生医药科技（北京）有限公司 人源化抗人表皮生长因子受体抗体及其应用
SG11201601770YA (en) * 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
CN106170299A (zh) * 2014-01-22 2016-11-30 小利兰斯坦福大学托管委员会 用于抗体和抗体负载树突状细胞介导治疗的方法和组合物
GB201402591D0 (en) 2014-02-14 2014-04-02 Memo Therapeutics Ag Method for recovering two or more genes, or gene products, encoding an immunoreceptor
EP3483593B1 (en) * 2014-03-26 2021-04-28 Siemens Healthcare Diagnostics Inc. Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
CA2965362A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
CN113713091A (zh) 2015-02-06 2021-11-30 新加坡国立大学 工程免疫细胞及其用途和生产方法
AU2016252877A1 (en) 2015-04-24 2017-11-09 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (EGFR) with a combination of three fully human monoclonal anti-EGFR antibodies
JP2019508428A (ja) 2016-03-15 2019-03-28 メリマック ファーマシューティカルズ インコーポレーティッド 抗ｅｒｂｂ３抗体を含む組み合わせ療法を用いて、ｅｒ＋、ｈｅｒ２−、ｈｒｇ＋乳癌を治療するための方法
EP3463451A1 (en) * 2016-05-26 2019-04-10 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
CN110366557B (zh) * 2016-12-23 2024-04-09 威特拉公司 结合多肽及其制备方法
EP3585814B1 (en) * 2017-02-22 2025-12-10 University of Saskatchewan Egfr-binding agents and uses thereof
WO2018166119A1 (zh) * 2017-03-14 2018-09-20 北京伟峰益民科技有限公司 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用
US11648269B2 (en) 2017-08-10 2023-05-16 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
US20200347140A1 (en) 2017-08-30 2020-11-05 Symphogen A/S Compositions and methods for treating cancer with anti-egfr antibodies
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
CN112566659A (zh) * 2018-01-25 2021-03-26 库利南Mica公司 Mica/b抗体和使用方法
SG11202010996QA (en) 2018-05-23 2020-12-30 Nat Univ Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
US11274035B2 (en) 2019-04-24 2022-03-15 X-Celeprint Limited Overhanging device structures and related methods of manufacture
US12162747B2 (en) 2018-12-03 2024-12-10 X-Celeprint Limited Enclosed cavity structures
US10456776B1 (en) 2019-02-21 2019-10-29 King Saud University Method of fabricating a photocatalyst for water splitting
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN111018990A (zh) * 2020-02-10 2020-04-17 张喜田 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
CA3233771A1 (en) 2021-10-04 2023-04-13 Les Laboratoires Servier Cancer therapy targeting nkg2a
AR127893A1 (es) 2021-12-10 2024-03-06 Servier Lab Terapia del cáncer dirigida a egfr

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1432064A (zh) 2000-03-23 2003-07-23 格林维尔医院系统公司 双功能癌症治疗剂
BR0110927A (pt) * 2000-05-19 2003-03-11 Scancell Ltd Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
CN100488563C (zh) 2001-02-19 2009-05-20 默克专利有限公司 免疫原性降低的经修饰抗egfr抗体
DE60234094D1 (de) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
JP4298498B2 (ja) * 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7662374B2 (en) 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
AU2003211342A1 (en) 2002-03-01 2003-09-16 Japan Envirochemicals, Ltd. Proteins capable of binding to environmental hormones and process for producing the same
EP1511769A2 (en) 2002-05-15 2005-03-09 Birgit Luber Egf receptor antagonists in the treatment of gastric cancer
EP1575491A4 (en) 2002-05-20 2006-09-27 Abgenix Inc TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
CN1703243B (zh) * 2002-10-10 2011-05-04 默克专利有限公司 针对erb-b1受体的药物组合物
US20060275766A1 (en) 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
JP4579836B2 (ja) 2004-01-23 2010-11-10 株式会社グリーンペプタイド 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド
US20110142822A1 (en) 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
KR20070038556A (ko) * 2004-07-20 2007-04-10 심포젠 에이/에스 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
AU2005263334C1 (en) 2004-07-20 2011-01-20 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
MX2007009963A (es) 2005-02-24 2007-09-26 Amgen Inc Mutaciones del receptor del factor de crecimiento epidermico.
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2006110478A2 (en) 2005-04-11 2006-10-19 Novartis Ag Mutations and polymorphisms of epidermal growth factor receptor
KR20080003422A (ko) 2005-04-14 2008-01-07 메르크 파텐트 게엠베하 종양 조직 내의 ｅｇｆｒ 유전자의 증가된 복제수에 기초한항-ｅｇｆｒ 항체 치료
EP1877083A2 (en) 2005-04-27 2008-01-16 Welson Pharmaceuticals, Inc. Antibodies for the treatment of cancers
EA019344B1 (ru) * 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
CN101627054A (zh) * 2005-07-11 2010-01-13 马克罗基因公司 用人源化抗cd16a抗体治疗自身免疫疾病的方法
US7850965B2 (en) 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
CA2638833A1 (en) 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
CA2677771A1 (en) 2007-03-01 2008-09-04 Symphogen A/S Method for cloning cognate antibodies
MX338151B (es) * 2007-03-01 2016-04-05 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
JP2008289483A (ja) 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
CN102137874B (zh) 2008-08-29 2015-02-18 西福根有限公司 抗表皮生长因子受体的重组抗体组合物
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition

Also Published As

Publication number Publication date
NZ597466A (en) 2013-08-30
TW200902552A (en) 2009-01-16
CN104151430A (zh) 2014-11-19
KR101805140B1 (ko) 2017-12-05
AU2008221118A1 (en) 2008-09-04
NZ578943A (en) 2012-09-28
EP2725036A1 (en) 2014-04-30
RU2013119724A (ru) 2014-11-10
EP2132229B1 (en) 2016-05-11
JP2010535012A (ja) 2010-11-18
HK1197252A1 (en) 2015-01-09
BRPI0808551B1 (pt) 2022-04-05
MX338151B (es) 2016-04-05
IL216850A (en) 2014-06-30
KR101676622B1 (ko) 2016-11-17
IL199725A (en) 2015-06-30
IL199725A0 (en) 2010-04-15
CA2676049C (en) 2018-04-10
US7887805B2 (en) 2011-02-15
HK1134826A1 (zh) 2010-06-11
IL216850A0 (en) 2012-01-31
US20110129855A1 (en) 2011-06-02
US8414896B2 (en) 2013-04-09
US20110135636A1 (en) 2011-06-09
ES2582386T3 (es) 2016-09-12
WO2008104183A2 (en) 2008-09-04
WO2008104183A3 (en) 2008-11-13
TWI426083B (zh) 2014-02-11
PL2132229T3 (pl) 2016-12-30
EP2725036B1 (en) 2017-10-25
AU2008221118B2 (en) 2013-10-03
EP2132229A2 (en) 2009-12-16
KR20160132132A (ko) 2016-11-16
CN101675075A (zh) 2010-03-17
JP5726417B2 (ja) 2015-06-03
US20090004192A1 (en) 2009-01-01
CA2676049A1 (en) 2008-09-04
MX2009008909A (es) 2009-08-28
CN101675075B (zh) 2014-06-18
KR20100014722A (ko) 2010-02-10
BRPI0808551A2 (pt) 2014-08-19

Similar Documents

Publication Publication Date Title
DK2132229T3 (en) Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
AU2009287163B2 (en) Recombinant anti-Epidermal Growth Factor Receptor antibody compositions
AU2013200209B9 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
RU2488596C2 (ru) Композиции рекомбинантных антител против рецептора эпидермального фактора роста
HK1134826B (en) Recombinant anti-epidermal growth factor receptor antibody compositions
AU2013200210A1 (en) Recombinant anti-epidermal growth factor receptor antibody compositions